ID   VIGLN_HUMAN             Reviewed;        1268 AA.
AC   Q00341; B4DTQ2; E7EM71; Q53QU2; Q9UCY3;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   16-DEC-2008, sequence version 2.
DT   12-APR-2017, entry version 171.
DE   RecName: Full=Vigilin;
DE   AltName: Full=High density lipoprotein-binding protein;
DE            Short=HDL-binding protein;
GN   Name=HDLBP; Synonyms=HBP, VGL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ALA-61.
RX   PubMed=1318310;
RA   McKnight G.L., Reasoner J., Gilbert T., Sundquist K.O., Hokland B.,
RA   McKernan P.A., Champagne J., Johnson C.J., Bailey M.C., Holly R.,
RA   O'Hara P.J., Oram J.F.;
RT   "Cloning and expression of a cellular high density lipoprotein-binding
RT   protein that is up-regulated by cholesterol loading of cells.";
RL   J. Biol. Chem. 267:12131-12141(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT
RP   ALA-61.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-61.
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-16; 73-87; 147-159; 208-222; 232-283; 315-324;
RP   350-377; 483-494; 496-503; 535-557; 649-663; 902-908 AND 1120-1137,
RP   CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT SER-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Mammary carcinoma, and Osteosarcoma;
RA   Bienvenut W.V., Matallanas D., Cooper W.N., Kolch W., Glen H.,
RA   Frame M.C.;
RL   Submitted (MAR-2008) to UniProtKB.
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=8605996; DOI=10.1016/0014-5793(96)00204-9;
RA   Kugler S., Grunweller A., Probst C., Klinger M., Mueller P.K.,
RA   Kruse C.;
RT   "Vigilin contains a functional nuclear localisation sequence and is
RT   present in both the cytoplasm and the nucleus.";
RL   FEBS Lett. 382:330-334(1996).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-437, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [14]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-8; SER-11; SER-31 AND
RP   SER-317, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-31; SER-1247 AND
RP   SER-1252, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   STRUCTURE BY NMR OF 142-222; 345-434; 645-727 AND 964-1200.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the 1st, 4th, 8th, 12th, 13th and 14th KH type-
RT   I domains from human vigilin.";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-568 AND VAL-939.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-61, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Appears to play a role in cell sterol metabolism. It may
CC       function to protect cells from over-accumulation of cholesterol.
CC   -!- INTERACTION:
CC       P49711:CTCF; NbExp=4; IntAct=EBI-1049478, EBI-932887;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:8605996}.
CC       Nucleus {ECO:0000269|PubMed:8605996}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q00341-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q00341-2; Sequence=VSP_044924, VSP_044925;
CC         Note=No experimental confirmation available.;
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M64098; AAA35962.1; -; mRNA.
DR   EMBL; AK300312; BAG62064.1; -; mRNA.
DR   EMBL; AC104841; AAY14717.1; -; Genomic_DNA.
DR   EMBL; BC001179; AAH01179.1; -; mRNA.
DR   CCDS; CCDS2547.1; -. [Q00341-1]
DR   CCDS; CCDS58760.1; -. [Q00341-2]
DR   PIR; A44125; A44125.
DR   RefSeq; NP_001230829.1; NM_001243900.2.
DR   RefSeq; NP_001307894.1; NM_001320965.1.
DR   RefSeq; NP_001307895.1; NM_001320966.1.
DR   RefSeq; NP_005327.1; NM_005336.5.
DR   RefSeq; NP_976221.1; NM_203346.4.
DR   RefSeq; XP_005247059.2; XM_005247002.3.
DR   RefSeq; XP_005247060.2; XM_005247003.4.
DR   RefSeq; XP_006712538.1; XM_006712475.3.
DR   RefSeq; XP_011509360.1; XM_011511058.2.
DR   RefSeq; XP_011509362.1; XM_011511060.2.
DR   RefSeq; XP_016859429.1; XM_017003940.1.
DR   UniGene; Hs.471851; -.
DR   UniGene; Hs.732361; -.
DR   PDB; 1VIG; NMR; -; A=432-502.
DR   PDB; 1VIH; NMR; -; A=432-502.
DR   PDB; 2CTE; NMR; -; A=142-222.
DR   PDB; 2CTF; NMR; -; A=346-434.
DR   PDB; 2CTJ; NMR; -; A=645-726.
DR   PDB; 2CTK; NMR; -; A=964-1054.
DR   PDB; 2CTL; NMR; -; A=1044-1127.
DR   PDB; 2CTM; NMR; -; A=1119-1200.
DR   PDBsum; 1VIG; -.
DR   PDBsum; 1VIH; -.
DR   PDBsum; 2CTE; -.
DR   PDBsum; 2CTF; -.
DR   PDBsum; 2CTJ; -.
DR   PDBsum; 2CTK; -.
DR   PDBsum; 2CTL; -.
DR   PDBsum; 2CTM; -.
DR   ProteinModelPortal; Q00341; -.
DR   SMR; Q00341; -.
DR   BioGrid; 109319; 87.
DR   IntAct; Q00341; 30.
DR   MINT; MINT-1189333; -.
DR   STRING; 9606.ENSP00000312042; -.
DR   iPTMnet; Q00341; -.
DR   PhosphoSitePlus; Q00341; -.
DR   SwissPalm; Q00341; -.
DR   BioMuta; HDLBP; -.
DR   DMDM; 218511884; -.
DR   EPD; Q00341; -.
DR   MaxQB; Q00341; -.
DR   PaxDb; Q00341; -.
DR   PeptideAtlas; Q00341; -.
DR   PRIDE; Q00341; -.
DR   DNASU; 3069; -.
DR   Ensembl; ENST00000427183; ENSP00000399139; ENSG00000115677.
DR   GeneID; 3069; -.
DR   KEGG; hsa:3069; -.
DR   UCSC; uc021vzg.1; human. [Q00341-1]
DR   CTD; 3069; -.
DR   DisGeNET; 3069; -.
DR   GeneCards; HDLBP; -.
DR   HGNC; HGNC:4857; HDLBP.
DR   HPA; CAB026457; -.
DR   HPA; HPA004189; -.
DR   MIM; 142695; gene.
DR   neXtProt; NX_Q00341; -.
DR   PharmGKB; PA29235; -.
DR   eggNOG; KOG2208; Eukaryota.
DR   eggNOG; ENOG410XQFV; LUCA.
DR   HOGENOM; HOG000007687; -.
DR   HOVERGEN; HBG054107; -.
DR   InParanoid; Q00341; -.
DR   PhylomeDB; Q00341; -.
DR   TreeFam; TF323767; -.
DR   Reactome; R-HSA-194223; HDL-mediated lipid transport.
DR   ChiTaRS; HDLBP; human.
DR   EvolutionaryTrace; Q00341; -.
DR   GeneWiki; HDLBP; -.
DR   GenomeRNAi; 3069; -.
DR   PRO; PR:Q00341; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000115677; -.
DR   CleanEx; HS_HDLBP; -.
DR   ExpressionAtlas; Q00341; baseline and differential.
DR   Genevisible; Q00341; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0034364; C:high-density lipoprotein particle; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008203; P:cholesterol metabolic process; TAS:ProtInc.
DR   GO; GO:0006869; P:lipid transport; IEA:UniProtKB-KW.
DR   GO; GO:0042157; P:lipoprotein metabolic process; TAS:Reactome.
DR   Gene3D; 3.30.1370.10; -; 15.
DR   Gene3D; 3.30.300.20; -; 1.
DR   InterPro; IPR004087; KH_dom.
DR   InterPro; IPR015946; KH_dom-like_a/b.
DR   InterPro; IPR004088; KH_dom_type_1.
DR   Pfam; PF00013; KH_1; 14.
DR   SMART; SM00322; KH; 14.
DR   SUPFAM; SSF54791; SSF54791; 13.
DR   PROSITE; PS50084; KH_TYPE_1; 14.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Cholesterol metabolism; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; HDL; Lipid metabolism; Lipid transport;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   RNA-binding; Steroid metabolism; Sterol metabolism; Transport.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.5}.
FT   CHAIN         2   1268       Vigilin.
FT                                /FTId=PRO_0000050131.
FT   DOMAIN      158    229       KH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      230    302       KH 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      303    371       KH 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      372    442       KH 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      443    514       KH 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      515    588       KH 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      589    660       KH 7. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      661    734       KH 8. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      735    807       KH 9. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      808    880       KH 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      881    979       KH 11. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN      980   1059       KH 12. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN     1060   1134       KH 13. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   DOMAIN     1135   1209       KH 14. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00117}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000269|Ref.5}.
FT   MOD_RES       8      8       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      11     11       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      31     31       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES      35     35       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z1A6}.
FT   MOD_RES     295    295       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES     296    296       Phosphothreonine. {ECO:0000255}.
FT   MOD_RES     317    317       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     437    437       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES     645    645       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Z1A6}.
FT   MOD_RES     991    991       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8VDJ3}.
FT   MOD_RES    1247   1247       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1252   1252       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1      1       M -> MHLAERDRWLFVATVMMHFVSIKSGFPGLCVGVRST
FT                                M (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044924.
FT   VAR_SEQ     291    359       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044925.
FT   VARIANT      61     61       S -> A (in dbSNP:rs11891776).
FT                                {ECO:0000244|PubMed:21269460,
FT                                ECO:0000269|PubMed:1318310,
FT                                ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_047976.
FT   VARIANT     229    229       V -> I (in dbSNP:rs7572799).
FT                                /FTId=VAR_055981.
FT   VARIANT     418    418       N -> S (in dbSNP:rs7578199).
FT                                /FTId=VAR_024511.
FT   VARIANT     568    568       K -> N (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036052.
FT   VARIANT     939    939       D -> V (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036053.
FT   VARIANT    1264   1264       W -> L (in dbSNP:rs12281).
FT                                /FTId=VAR_029279.
FT   STRAND      151    156       {ECO:0000244|PDB:2CTE}.
FT   TURN        159    161       {ECO:0000244|PDB:2CTE}.
FT   HELIX       162    166       {ECO:0000244|PDB:2CTE}.
FT   STRAND      168    170       {ECO:0000244|PDB:2CTE}.
FT   HELIX       172    179       {ECO:0000244|PDB:2CTE}.
FT   STRAND      195    200       {ECO:0000244|PDB:2CTE}.
FT   HELIX       202    220       {ECO:0000244|PDB:2CTE}.
FT   STRAND      365    370       {ECO:0000244|PDB:2CTF}.
FT   HELIX       376    380       {ECO:0000244|PDB:2CTF}.
FT   TURN        381    384       {ECO:0000244|PDB:2CTF}.
FT   HELIX       386    393       {ECO:0000244|PDB:2CTF}.
FT   STRAND      395    401       {ECO:0000244|PDB:2CTF}.
FT   STRAND      403    405       {ECO:0000244|PDB:2CTF}.
FT   STRAND      407    412       {ECO:0000244|PDB:2CTF}.
FT   HELIX       414    434       {ECO:0000244|PDB:2CTF}.
FT   STRAND      436    442       {ECO:0000244|PDB:1VIG}.
FT   HELIX       446    450       {ECO:0000244|PDB:1VIG}.
FT   TURN        452    454       {ECO:0000244|PDB:1VIH}.
FT   HELIX       457    464       {ECO:0000244|PDB:1VIG}.
FT   STRAND      468    470       {ECO:0000244|PDB:1VIG}.
FT   STRAND      476    487       {ECO:0000244|PDB:1VIG}.
FT   HELIX       488    499       {ECO:0000244|PDB:1VIG}.
FT   STRAND      656    659       {ECO:0000244|PDB:2CTJ}.
FT   HELIX       662    669       {ECO:0000244|PDB:2CTJ}.
FT   STRAND      671    673       {ECO:0000244|PDB:2CTJ}.
FT   HELIX       674    683       {ECO:0000244|PDB:2CTJ}.
FT   STRAND      687    689       {ECO:0000244|PDB:2CTJ}.
FT   TURN        693    696       {ECO:0000244|PDB:2CTJ}.
FT   STRAND      699    704       {ECO:0000244|PDB:2CTJ}.
FT   HELIX       706    723       {ECO:0000244|PDB:2CTJ}.
FT   STRAND      973    978       {ECO:0000244|PDB:2CTK}.
FT   HELIX       981    988       {ECO:0000244|PDB:2CTK}.
FT   STRAND      990    992       {ECO:0000244|PDB:2CTK}.
FT   HELIX       993   1001       {ECO:0000244|PDB:2CTK}.
FT   STRAND     1005   1007       {ECO:0000244|PDB:2CTK}.
FT   TURN       1011   1013       {ECO:0000244|PDB:2CTK}.
FT   STRAND     1017   1022       {ECO:0000244|PDB:2CTK}.
FT   HELIX      1024   1050       {ECO:0000244|PDB:2CTK}.
FT   STRAND     1054   1058       {ECO:0000244|PDB:2CTL}.
FT   TURN       1061   1063       {ECO:0000244|PDB:2CTL}.
FT   HELIX      1064   1067       {ECO:0000244|PDB:2CTL}.
FT   STRAND     1070   1072       {ECO:0000244|PDB:2CTL}.
FT   HELIX      1074   1082       {ECO:0000244|PDB:2CTL}.
FT   STRAND     1085   1087       {ECO:0000244|PDB:2CTL}.
FT   TURN       1091   1093       {ECO:0000244|PDB:2CTL}.
FT   STRAND     1098   1105       {ECO:0000244|PDB:2CTL}.
FT   HELIX      1107   1126       {ECO:0000244|PDB:2CTL}.
FT   STRAND     1130   1133       {ECO:0000244|PDB:2CTM}.
FT   TURN       1136   1138       {ECO:0000244|PDB:2CTM}.
FT   HELIX      1139   1143       {ECO:0000244|PDB:2CTM}.
FT   STRAND     1145   1147       {ECO:0000244|PDB:2CTM}.
FT   HELIX      1149   1157       {ECO:0000244|PDB:2CTM}.
FT   STRAND     1160   1162       {ECO:0000244|PDB:2CTM}.
FT   STRAND     1173   1178       {ECO:0000244|PDB:2CTM}.
FT   HELIX      1180   1198       {ECO:0000244|PDB:2CTM}.
SQ   SEQUENCE   1268 AA;  141456 MW;  530C61A3CA9239CD CRC64;
     MSSVAVLTQE SFAEHRSGLV PQQIKVATLN SEEESDPPTY KDAFPPLPEK AACLESAQEP
     SGAWGNKIRP IKASVITQVF HVPLEERKYK DMNQFGEGEQ AKICLEIMQR TGAHLELSLA
     KDQGLSIMVS GKLDAVMKAR KDIVARLQTQ ASATVAIPKE HHRFVIGKNG EKLQDLELKT
     ATKIQIPRPD DPSNQIKITG TKEGIEKARH EVLLISAEQD KRAVERLEVE KAFHPFIAGP
     YNRLVGEIMQ ETGTRINIPP PSVNRTEIVF TGEKEQLAQA VARIKKIYEE KKKKTTTIAV
     EVKKSQHKYV IGPKGNSLQE ILERTGVSVE IPPSDSISET VILRGEPEKL GQALTEVYAK
     ANSFTVSSVA APSWLHRFII GKKGQNLAKI TQQMPKVHIE FTEGEDKITL EGPTEDVNVA
     QEQIEGMVKD LINRMDYVEI NIDHKFHRHL IGKSGANINR IKDQYKVSVR IPPDSEKSNL
     IRIEGDPQGV QQAKRELLEL ASRMENERTK DLIIEQRFHR TIIGQKGERI REIRDKFPEV
     IINFPDPAQK SDIVQLRGPK NEVEKCTKYM QKMVADLVEN SYSISVPIFK QFHKNIIGKG
     GANIKKIREE SNTKIDLPAE NSNSETIIIT GKRANCEAAR SRILSIQKDL ANIAEVEVSI
     PAKLHNSLIG TKGRLIRSIM EECGGVHIHF PVEGSGSDTV VIRGPSSDVE KAKKQLLHLA
     EEKQTKSFTV DIRAKPEYHK FLIGKGGGKI RKVRDSTGAR VIFPAAEDKD QDLITIIGKE
     DAVREAQKEL EALIQNLDNV VEDSMLVDPK HHRHFVIRRG QVLREIAEEY GGVMVSFPRS
     GTQSDKVTLK GAKDCVEAAK KRIQEIIEDL EAQVTLECAI PQKFHRSVMG PKGSRIQQIT
     RDFSVQIKFP DREENAVHST EPVVQENGDE AGEGREAKDC DPGSPRRCDI IIISGRKEKC
     EAAKEALEAL VPVTIEVEVP FDLHRYVIGQ KGSGIRKMMD EFEVNIHVPA PELQSDIIAI
     TGLAANLDRA KAGLLERVKE LQAEQEDRAL RSFKLSVTVD PKYHPKIIGR KGAVITQIRL
     EHDVNIQFPD KDDGNQPQDQ ITITGYEKNT EAARDAILRI VGELEQMVSE DVPLDHRVHA
     RIIGARGKAI RKIMDEFKVD IRFPQSGAPD PNCVTVTGLP ENVEEAIDHI LNLEEEYLAD
     VVDSEALQVY MKPPAHEEAK APSRGFVVRD APWTASSSEK APDMSSSEEF PSFGAQVAPK
     TLPWGPKR
//
